Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MCK
MCK logo

MCK Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
811.900
Open
793.560
VWAP
805.07
Vol
237.85K
Mkt Cap
91.82B
Low
793.560
Amount
191.49M
EV/EBITDA(TTM)
14.36
Total Shares
117.08M
EV
95.95B
EV/OCF(TTM)
15.59
P/S(TTM)
0.24
McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.
Show More

Events Timeline

(ET)
2026-06-02
08:20:00
McKesson Completes Apollo Investment in MMS
select

News

Yahoo Finance
6.5
06-24Yahoo Finance
Amgen vs Iovance: Investment Comparison
  • Amgen's Stability: In FY 2025, Amgen reported nearly $36.7 billion in revenue, a 9.9% increase year-over-year, with a net income of approximately $7.7 billion and a net margin of about 21%, showcasing its strong profitability and stability in the global market.
  • Iovance's Rapid Growth: Iovance achieved approximately $263.5 million in revenue for FY 2025, marking a 60.6% increase, yet it reported a net loss of nearly $391 million, indicating its innovative potential in cancer treatment but highlighting its lack of profitability.
  • Risk Comparison: Amgen faces risks from government pricing regulations and competition from biosimilars, while Iovance must navigate the complexities of manufacturing personalized therapies and uncertainties regarding market adoption, which could impact their future market performance.
  • Valuation Differences: Amgen has a forward P/E ratio of 15.1, reflecting its value as a mature company, whereas Iovance, still unprofitable, has a P/S ratio of 5.4, indicating its high-risk investment profile in the early growth stage.
NASDAQ.COM
2.0
06-19NASDAQ.COM
Cardinal Health Continues Growth with Stock Price Surge
  • Outstanding Stock Performance: Cardinal Health achieved a remarkable 74% stock price increase in 2025, followed by a 7.9% rise year-to-date in 2026, reflecting sustained investor confidence in its growth strategy, significantly outperforming peers McKesson and Cencora.
  • Enhanced Profitability: In its fiscal Q3 2026 earnings report, the company reported a 35% EPS growth and raised its earnings guidance again, underscoring management's confidence in sustained operational momentum despite macro uncertainties and pricing pressures.
  • Strong Specialty Pharmaceutical Business: Cardinal Health's Pharmaceutical and Specialty Solutions segment saw an 11% revenue increase to $56.1 billion and an 18% profit rise in Q3, with expectations for specialty sales to exceed $50 billion in fiscal 2026, indicating robust growth potential in the market.
  • Rapid Expansion of New Businesses: The company's
NASDAQ.COM
4.5
06-10NASDAQ.COM
IYK ETF 52-Week Price Range Analysis
  • Price Fluctuation Analysis: The IYK ETF has a 52-week low of $65.21 and a high of $77.70, with the last trade at $73.34, indicating stability within its trading range that may attract investor interest.
  • Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
  • ETF Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting liquidity and market performance.
  • Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF shares outstanding highlights significant inflows (new units created) or outflows (old units destroyed), which can affect the underlying stocks held by the ETF and influence overall market dynamics.
CNBC
6.5
06-10CNBC
Market Dynamics and Investment Strategy Analysis
  • Market Opening Outlook: Following President Trump's remarks about Iran's delay in peace negotiations, stocks are expected to open lower, with rising oil prices; although the May consumer price index met expectations, the market's anticipation of a Fed interest rate hike indicates investor caution regarding future economic conditions.
  • SpaceX IPO Activity: As investors liquidate stock positions to buy into the SpaceX IPO, this trend is expected to intensify ahead of Friday's trading start, with the need for rebalancing in the Nasdaq 100 index making large-cap companies significant contributors, reflecting strong market interest in emerging tech firms.
  • Enterprise Model Launch: Anthropic unveiled its high-powered enterprise model, Claude Fable 5, based on Mythos, promising a measured release approach due to its effectiveness in identifying security flaws, showcasing the company's innovative potential in the AI sector.
  • Analyst Rating Changes: Evercore ISI upgraded Entergy from hold to buy, raising the price target from $115 to $121, as analysts expressed confidence in the management's ability to attract significant demand, reflecting an optimistic outlook for the electric power industry.
seekingalpha
9.5
05-08seekingalpha
McKesson Reports Strong Q4 2026 Earnings with Strategic Growth Plans
  • Strong Financial Performance: McKesson reported an adjusted earnings per diluted share of $11.69 for Q4 2026, with consolidated revenues increasing by 6% to $96.3 billion and gross profit rising by 14% to $3.9 billion, indicating robust market performance and profitability.
  • Shareholder Return Initiatives: The company returned $5.1 billion to shareholders through share repurchases in fiscal 2026 and anticipates free cash flow to remain between $4.5 billion and $4.9 billion in fiscal 2027, reflecting management's confidence in future cash generation and commitment to shareholders.
  • Separation Progress: McKesson is advancing its plan to spin off its Medical-Surgical Solutions segment into an independent entity, having secured a $1.25 billion strategic investment from Apollo, which is expected to unlock shareholder value and enhance strategic clarity.
  • Future Growth Outlook: The company projects adjusted earnings per diluted share in the range of $43.80 to $44.60 for fiscal 2027, with revenue growth expectations of 14.5% to 18.5% in the oncology and multispecialty segment, showcasing a positive outlook on new market opportunities.
CNBC
4.5
05-07CNBC
Market Dynamics: Oil Prices and Tech Stocks Fluctuate
  • Oil Price Recovery: West Texas Intermediate crude oil prices rebounded above $97 per barrel after a morning dip, reflecting cautious optimism about future demand, which could impact related energy stocks' performance.
  • Divergent Tech Stock Performance: As AI-related stocks pull back, cybersecurity software stocks like CrowdStrike and Palo Alto Networks surged, crossing $500 and $190 respectively for the first time, indicating increased market confidence in their business models and potentially attracting more investor interest.
  • Boeing Stock Rise: Boeing's shares rose as CEO Kelly Ortberg is set to accompany President Trump on his trip to China, with the market anticipating a major order of up to 500 planes, although skepticism remains regarding the order's realization.
  • Employment Data Expectations: Economists forecast a 65,000 increase in April's nonfarm payrolls with the unemployment rate steady at 4.3%, while average hourly earnings are expected to rise by 3.8%, providing crucial economic health indicators that could influence investor confidence.
Wall Street analysts forecast MCK stock price to rise
14 Analyst Rating
Wall Street analysts forecast MCK stock price to rise
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
880.00
Averages
942.83
High
1000.00
Current: 0.000
sliders
Low
880.00
Averages
942.83
High
1000.00
Citi
Buy
to
Buy
downgrade
$975 -> $945
AI Analysis
2026-05-14
Reason
Citi
Price Target
$975 -> $945
AI Analysis
2026-05-14
downgrade
Buy
to
Buy
Reason
Citi lowered the firm's price target on McKesson to $945 from $975 and keeps a Buy rating on the shares.
UBS
Kevin Caliendo
Buy
maintain
2026-05-08
Reason
UBS
Kevin Caliendo
Price Target
2026-05-08
maintain
Buy
Reason
UBS analyst Kevin Caliendo raised the firm's price target on McKesson to $1,050 from $1,000 and keeps a Buy rating on the shares. Despite the "messy" Q4 print, the initial FY27 outlook looks "good enough," the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MCK
Unlock Now

Valuation Metrics

The current forward P/E ratio for McKesson Corp (MCK.N) is 17.76, compared to its 5-year average forward P/E of 15.68. For a more detailed relative valuation and DCF analysis to assess McKesson Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
15.68
Current PE
17.76
Overvalued PE
18.68
Undervalued PE
12.68

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
11.85
Current EV/EBITDA
9.07
Overvalued EV/EBITDA
14.28
Undervalued EV/EBITDA
9.42

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.19
Current PS
0.20
Overvalued PS
0.22
Undervalued PS
0.16

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

list of strong buy stocks
Intellectia · 202 candidates
Analyst Consensus: Strong BuyRelative Vol: >= 1.50Is Optionable: True
Ticker
Name
Market Cap$
top bottom
NVDA logo
NVDA
NVIDIA Corp
4.85T
GOOG logo
GOOG
Alphabet Inc
4.63T
MSFT logo
MSFT
Microsoft Corp
3.03T
AMZN logo
AMZN
Amazon.com Inc
2.85T
META logo
META
Meta Platforms Inc
1.55T
LLY logo
LLY
Eli Lilly and Co
883.03B
what is the best stock to buy right now
Intellectia · 57 candidates
Market Cap: >= 30.00BRegion: USAnalyst Consensus: Strong BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Annual Eps Yoy Growth: >= 10.0%Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
WDC logo
WDC
Western Digital Corp
116.44B
GE logo
GE
General Electric Co
322.17B
MU logo
MU
Micron Technology Inc
474.31B
MCK logo
MCK
McKesson Corp
106.03B
FIX logo
FIX
Comfort Systems USA Inc
56.04B
AVGO logo
AVGO
Broadcom Inc
1.76T
good long term option call
Intellectia · 10 candidates
Market Cap: >= 100.00BMarket Cap Category: largeAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Is Optionable: TrueAnnual Revenue Yoy Growth: >= 15.0%
Ticker
Name
Market Cap$
top bottom
KLAC logo
KLAC
KLA Corp
198.11B
ANET logo
ANET
Arista Networks Inc
170.74B
APH logo
APH
Amphenol Corp
160.62B
ADI logo
ADI
Analog Devices Inc
152.41B
WELL logo
WELL
Welltower Inc
136.06B
ENB logo
ENB
Enbridge Inc
118.20B
what to buy or sell now
Intellectia · 39 candidates
Market Cap: >= 20.00BRevenue 5yr Cagr: >= 8Pe Ttm: 12 - 30Moving Average Relationship: PriceAboveMA200Is Index Component: GSPC, NDX, DJI
Ticker
Name
Market Cap$
top bottom
XOM logo
XOM
Exxon Mobil Corp
639.72B
CMI logo
CMI
Cummins Inc
74.44B
HAL logo
HAL
Halliburton Co
29.18B
NEM logo
NEM
Newmont Corporation
124.54B
AEE logo
AEE
Ameren Corp
30.41B
REGN logo
REGN
Regeneron Pharmaceuticals Inc
78.93B
atocks to buy tomoroow
Intellectia · 46 candidates
Moving Average Relationship: PriceAboveMA20Month Price Change Pct: $5.00 - $25.00Is Index Component: GSPC, NDXAnnual Revenue Yoy Growth: >= 10.0%Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
MCK logo
MCK
McKesson Corp
120.94B
PWR logo
PWR
Quanta Services Inc
83.96B
BALL logo
BALL
Ball Corp
17.86B
IRM logo
IRM
Iron Mountain Inc
32.05B
NEM logo
NEM
Newmont Corporation
141.42B
NFLX logo
NFLX
Netflix Inc
406.34B
strong buy best stock to trade next week ?
Intellectia · 84 candidates
Market Cap: >= 10.00BMarket Cap Category: mega, largeAnalyst Consensus: Strong BuyList Exchange: XNYS, XNASOne Week Rise Prob: >= 70Monthly Average Dollar Volume: >= 3,000,000
Ticker
Name
Market Cap$
top bottom
ECL logo
ECL
Ecolab Inc
86.95B
ASND logo
ASND
Ascendis Pharma A/S
14.47B
WBS logo
WBS
Webster Financial Corp
11.63B
NU logo
NU
Nu Holdings Ltd
72.74B
MP logo
MP
MP Materials Corp
10.46B
TSM logo
TSM
Taiwan Semiconductor Manufacturing Co Ltd
1.94T
what should I buy to make some quick cash
Intellectia · 29 candidates
Market Cap: >= 2.00BRegion: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20One Week Rise Prob: >= 65One Week Predict Return: >= 5.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
RELY logo
RELY
Remitly Global Inc
2.85B
AVAV logo
AVAV
AeroVironment Inc
13.25B
KTOS logo
KTOS
Kratos Defense and Security Solutions Inc
16.41B
LBRT logo
LBRT
Liberty Energy Inc
4.39B
VIST logo
VIST
Vista Energy SAB de CV
5.78B
GLBE logo
GLBE
Global-E Online Ltd
5.91B
what should I buy with 10k today
Intellectia · 72 candidates
Market Cap: >= 10.00BQuarter Revenue Yoy Growth: >= 10.0%Analyst Consensus: Strong Buy, Moderate BuyPe Ttm: 10 - 35Is Index Component: GSPC, NDX
Ticker
Name
Market Cap$
top bottom
GOOG logo
GOOG
Alphabet Inc
3.70T
MSFT logo
MSFT
Microsoft Corp
2.98T
AMZN logo
AMZN
Amazon.com Inc
2.13T
META logo
META
Meta Platforms Inc
1.62T
V logo
V
Visa Inc
598.64B
MU logo
MU
Micron Technology Inc
463.33B
welche us Aktien soll ich heute kaufen?
Intellectia · 53 candidates
Market Cap: >= 0Revenue 5yr Cagr: >= 8Pe Ttm: 10 - 30List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA200Is Index Component: GSPC
Ticker
Name
Market Cap$
top bottom
JPM logo
JPM
JPMorgan Chase & Co
813.77B
MU logo
MU
Micron Technology Inc
439.39B
MS logo
MS
Morgan Stanley
287.52B
GS logo
GS
Goldman Sachs Group Inc
277.15B
MRK logo
MRK
Merck & Co Inc
266.87B
AXP logo
AXP
American Express Co
247.25B
Top Biotechnology/Health Tech
Intellectia · 82 candidates
Weekly Average Turnover: >= 1,000,000Year Price Change Pct: >= $10.00Annual Eps Yoy Growth: >= 10.0%Annual Revenue Yoy Growth: >= 10.0%
Ticker
Name
Market Cap$
top bottom
LLY logo
LLY
Eli Lilly and Co
1.02T
AZN logo
AZN
AstraZeneca PLC
280.73B
NVS logo
NVS
Novartis AG
278.44B
MCK logo
MCK
McKesson Corp
101.61B
ARGX logo
ARGX
argenx SE
50.52B
ALNY logo
ALNY
Alnylam Pharmaceuticals Inc
48.28B

Whales Holding MCK

C
Cookson Peirce & Co Inc
Holding
MCK
+23.25%
3M Return
W
Walleye Capital LLC
Holding
MCK
+22.85%
3M Return
T
TCW Group, Inc.
Holding
MCK
+21.57%
3M Return
F
Farallon Capital Management, L.L.C.
Holding
MCK
+17.65%
3M Return
G
Glenview Capital Management, LLC
Holding
MCK
+16.67%
3M Return
O
Oak Associates, ltd.
Holding
MCK
+15.78%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is McKesson Corp (MCK) stock price today?

The current price of MCK is 809.74 USD — it has increased 3.25

What is McKesson Corp (MCK)'s business?

McKesson Corporation is a diversified healthcare services company, which focuses on advancing health outcomes for patients everywhere. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (U.S.). The Prescription Technology Solutions (RxTS) segment helps solve medication access, affordability and adherence challenges for patients by working across healthcare to connect patients, pharmacies, pharmacy benefit managers, health plans, and biopharma companies. The Medical-Surgical Solutions provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, hospital reference labs, and home healthcare agencies. The International segment provides distribution and services to wholesale, institutional, and retail customers in Canada and Norway. It also offers oncology and specialty solutions.

What is the price predicton of MCK Stock?

Wall Street analysts forecast MCK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MCK is942.83 USD with a low forecast of 880.00 USD and a high forecast of 1000.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is McKesson Corp (MCK)'s revenue for the last quarter?

McKesson Corp revenue for the last quarter amounts to 96.30B USD, increased 6.02

What is McKesson Corp (MCK)'s earnings per share (EPS) for the last quarter?

McKesson Corp. EPS for the last quarter amounts to 13.69 USD, increased 36.90

How many employees does McKesson Corp (MCK). have?

McKesson Corp (MCK) has 43000 emplpoyees as of July 07 2026.

What is McKesson Corp (MCK) market cap?

Today MCK has the market capitalization of 91.82B USD.